Supriya Lifescience Ltd approves Q2 FY27 results with revenue of ₹206.30 crore and net profit of ₹29.25 crore.
- Revenue rose 8.7% sequentially and 3.2% year on year; net profit increased 21.7% sequentially and declined 42.0% year on year.
- Derived EBIT margin was 17.4%; no exceptional items were reported.
- Auditor’s limited review report expressed no concerns.
- Appointed Mangesh Vaze Chief Operating Officer and Senior Management Personnel, effective November 6, 2026.
